Aegera Initiates Phase I Diabetic Neuropathy Study
Posted on: Wednesday, 19 March 2008, 12:01 CDT
Aegera Therapeutics has started a Phase I, first-in-man, clinical trial for AEG33773, a novel, orally bioavailable small molecule in development for the treatment of painful diabetic neuropathy.
The Phase I study will evaluate the safety, tolerability and pharmacokinetic profile of AEG33773 using a randomized, double blind, placebo controlled, single ascending dose design in healthy male volunteers.
Michael Berendt, president and CEO of Aegera, said: "The Aegera team has successfully filed regulatory applications for two potential blockbuster compounds, AEG33773 and AEG40826, in the last three months while initiating multiple Phase II trials for our lead program AEG35156. Aegera now has four unique programs in clinical development and is poised to deliver significant clinical data over the next 12-18 months."
Source: Datamonitor
Related Articles
- Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
- Aegera Therapeutics Collaboration With Human Genome Sciences Leads to the Initiation of a Phase 1 Clinical Trial With Lead IAP Inhibitor HGS1029 and Receipt of First Milestone Payment
- Aegera Initiates Phase 1 Clinical Trial of AEG33773 - A Small Molecule in Development for Diabetic Neuropathic Pain
- CORRECTING and REPLACING Progenics Announces Positive Top-Line Results From Pivotal Phase 3 Clinical Trial of MNTX in Opioid-Induced Constipation
- Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Non-Hodgkin's Lymphoma
- Human Genome Sciences Completes Patient Enrollment in a Phase 2 Clinical Trial of HGS-ETR1 for the Treatment of Colorectal Cancer
- Cougar Biotechnology Presents CB7630 Phase I Clinical Data at the 2005 Prostate Cancer Symposium
- Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA975, an Oral Prodrug of Isatoribine for Hepatitis C
- ImClone Systems Commences Patient Treatment in U.S. Phase I Clinical Trial Of IMC-1121B
- Microbia Announces Initiation of Phase I Clinical Trial for Novel, ORAL IBS Treatment
 |
 |
User Comments (0)
RSS Feeds